Core Insights - Progyny, Inc. reported a quarterly revenue of $298.4 million, reflecting a 10.6% growth compared to the previous year, marking the tenth consecutive year of revenue growth [1][8][12] - The company generated $52.2 million in quarterly operating cash flow and provided financial guidance for 2025, projecting revenue growth of 1% to 5% [1][28] - The CEO highlighted improved member engagement trends as the company enters its tenth year in the market, emphasizing the unique approach to value-based care [2][3] Financial Highlights - **Fourth Quarter 2024 Results**: - Revenue: $298.4 million, up 10.6% from $269.9 million in Q4 2023 [4][8] - Gross Profit: $63.4 million, an 11% increase from $56.9 million in Q4 2023 [9] - Net Income: $10.5 million, or $0.12 per diluted share, down from $13.5 million, or $0.13 per diluted share in Q4 2023 [10][11] - Adjusted EBITDA: $47.5 million, a 10% increase from $43.2 million in Q4 2023 [11] - **Full Year 2024 Results**: - Revenue: $1,167.2 million, a 7.2% increase from $1,088.6 million in 2023 [12] - Gross Profit: $253.4 million, up 6.1% from $238.8 million in 2023 [13] - Net Income: $54.3 million, or $0.57 per diluted share, down from $62.0 million, or $0.62 per diluted share in 2023 [14] - Adjusted EBITDA: $198.8 million, a 6.2% increase from $187.1 million in 2023 [15] Cash Flow and Financial Position - Net cash provided by operating activities for 2024 was $179.1 million, compared to $188.8 million in 2023 [17] - As of December 31, 2024, the company had total working capital of approximately $304.1 million and no debt [18] - The company repurchased 3,248,298 shares for $52.5 million in Q4 2024, totaling 12,382,193 shares repurchased in 2024 [22] Client and Market Metrics - The company had 473 clients as of December 31, 2024, compared to 392 clients a year earlier [23] - Fertility benefit services revenue was $187.5 million in Q4 2024, a 9% increase from $171.3 million in Q4 2023 [19] - Pharmacy benefit services revenue was $111.0 million in Q4 2024, a 13% increase from $98.6 million in Q4 2023 [19] Financial Outlook - For the full year 2025, revenue is projected to be between $1.175 billion and $1.225 billion, with net income expected to be between $45.0 million and $53.9 million [28] - For Q1 2025, revenue is projected to be between $300.0 million and $318.0 million, reflecting growth of 8% to 14% [28]

Core Viewpoint - The market anticipates Progyny (PGNY) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Progyny is expected to post quarterly earnings of $0.37 per share, reflecting a year-over-year increase of +15.6%, with revenues projected at $280.37 million, up 3.9% from the previous year [3]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Progyny is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.18%, indicating a bullish outlook from analysts [10]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which increases the likelihood of a positive surprise to nearly 70% [8]. Historical Performance - Progyny has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters, including a +8.11% surprise in the most recent quarter [12][13]. Conclusion - Progyny is positioned as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond earnings results [16].

Core Viewpoint - Progyny, Inc. will report its financial results for the fourth quarter and full year of 2024 on February 27, 2025, and will host a conference call to discuss these results [1] Company Overview - Progyny is a transformative solution for fertility, family building, and women's health benefits, trusted by leading employers and health plans [4] - The company aims to enable individuals to achieve their family and health aspirations through comprehensive and inclusive solutions [4] Financial Reporting - The financial results will be announced after market close on February 27, 2025, followed by a conference call at 4:45 p.m. Eastern Time [1] - An audio replay of the conference call will be available until March 6, 2025 [2] Access Information - U.S. participants can join the conference call by dialing 1.866.825.7331, while international participants can call 1.973.413.6106, using the passcode 265484 [2] - A live webcast and archive of the call will be accessible on the company's website [3]

Core Viewpoint - Progyny (PGNY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Movement - The change in earnings estimates is a powerful factor affecting near-term stock price movements, with institutional investors using these estimates to determine fair value [3]. - Progyny's rising earnings estimates and the subsequent rating upgrade suggest an improvement in the company's underlying business, likely leading to an increase in stock price [4]. Zacks Rank System - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks into five groups, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are recognized for superior earnings estimate revisions [8][9]. Specifics on Progyny's Earnings Estimates - For the fiscal year ending December 2024, Progyny is expected to earn $1.57 per share, reflecting a 12.1% increase from the previous year, with a 6.1% rise in the Zacks Consensus Estimate over the past three months [7].

Core Viewpoint - Progyny (PGNY) is well-positioned to continue its earnings-beat streak in the upcoming report, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 13.78% [1][3]. Earnings Performance - In the last reported quarter, Progyny achieved earnings of $0.40 per share, surpassing the Zacks Consensus Estimate of $0.37 per share, resulting in a surprise of 8.11% [2]. - In the previous quarter, the company was expected to post earnings of $0.36 per share but delivered $0.43 per share, yielding a surprise of 19.44% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Progyny, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [3][6]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [4]. Earnings ESP Metric - The current Earnings ESP for Progyny is +0.56%, suggesting analysts are optimistic about its near-term earnings potential [6]. - A negative Earnings ESP reduces predictive power but does not necessarily indicate an earnings miss [6]. Importance of Earnings ESP - Many companies beat consensus EPS estimates, but this is not the sole reason for share price gains; some stocks may remain stable even if they miss estimates [7]. - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the chances of successful investment decisions [7].

Core Insights - Progyny, Inc. has acquired BenefitBump to enhance its parental leave benefits navigation program, aiming to provide comprehensive support for families from pregnancy to early childhood [1][3] - The acquisition is part of Progyny's strategy to address the needs of parents, with 90% of parents seeking more support to manage work and home responsibilities [2][4] Company Overview - Progyny is a transformative solution in fertility, family building, and women's health benefits, trusted by leading employers and health plans [5][6] - The company offers concierge support, coaching, education, and access to a network of specialists, driving optimal clinical outcomes and reducing healthcare costs [6][7] Enhanced Service Offerings - The integration of BenefitBump will provide high-touch, guided support, easing the complexities of navigating employee benefits and leave programs for new parents [3][4] - The enhanced suite of services will include clinical social worker-led parental wellness programs, comprehensive parental leave navigation, and clinician-facilitated peer support groups [8]

Company Overview - Progyny, Inc. (NASDAQ:PGNY) is a transformative solution for fertility, family building, and women's health benefits, trusted by leading employers and health plans [5][6] - The company aims to empower patients through concierge support, coaching, education, and access to a premier network of specialists, driving optimal clinical outcomes while reducing healthcare costs [6] Leadership Appointment - Debra Morris, a 30-year healthcare industry veteran, has been appointed to Progyny's board of directors effective January 16, 2025 [1][2] - Morris currently serves as President of AccessHope and has previously held the position of EVP and CFO at Apria Healthcare, showcasing her ability to navigate complex industry challenges [2] Strategic Impact - The CEO of Progyny, Pete Anevski, emphasized that Morris's expertise in scaling organizations and understanding healthcare systems will be invaluable as the company expands its services [3] - Morris expressed her personal connection to the mission of Progyny, highlighting the company's innovative model and commitment to empowering women and families [3] Recognition and Growth - Progyny has received multiple accolades, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50, reflecting its leadership and growth in the industry [7]

Anticipates Fourth Quarter and Full Year Results to be Slightly Above Previously Provided Financial GuidanceNEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a transformative fertility, family building and women’s health benefits solution, today announced that the Company is participating in the 43rd Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2024. In its Novemb ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Progyny, Inc. related to self-dealing, which may entitle shareholders to damages and corporate governance reforms [1]. Group 1 - The investigation focuses on whether the actions of Progyny's officers and directors constitute self-dealing [1]. - Shareholders may have the right to seek damages and advocate for changes in corporate governance as a result of the investigation [1]. Group 2 - Long-term shareholders of Progyny are encouraged to contact Kuehn Law for a free consultation regarding their rights [2]. - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of timely action for shareholders [2]. Group 3 - The firm highlights the significance of shareholder participation in maintaining the integrity and fairness of financial markets [3]. - Kuehn Law promotes the idea that every shareholder's voice contributes to their investment future [3].

Paul Franke's Background and Investment Approach - Paul Franke is a private investor and speculator with 38 years of trading experience, known for his contrarian stock selection style and algorithm-based analysis of fundamental and technical data [1] - He developed the "Victory Formation" system, which identifies supply/demand imbalances through specific stock price and volume movements, and suggests using 10% or 20% stop-loss levels on individual choices [1] - Franke recommends a diversified approach of owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1] - His "Bottom Fishing Club" articles focus on deep-value candidates or stocks experiencing a major reversal in technical momentum to the upside, while "Volume Breakout Report" articles discuss positive trend changes backed by strong price and volume trading action [1] Paul Franke's Achievements and Rankings - Franke was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest during the 1990s [1] - He was ranked 1 in the Motley Fool CAPS stock picking contest during parts of 2008 and 2009, out of 60,000+ portfolios [1] - As of September 2024, Franke was ranked in the Top 3% of bloggers by TipRanks for 12-month stock picking performance on suggestions made over the last decade [1] Paul Franke's Professional Experience - Franke was Editor and Publisher of the Maverick Investor newsletter during the 1990s, widely quoted by CNBC, Barron's, the Washington Post, and Investor's Business Daily [1] - He served as Director of Research at Quantemonics Investing from 2010-13, running several model portfolios on the Covestor.com mirror platform, including the least volatile, lowest beta, fully-invested equity portfolio on the site [1]